Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - esketamine hidrochloridas - depresijos sutrikimas - kiti antidepresantai - spravato, kartu su ssri ar snri, yra nurodyta suaugusiųjų gydymas-atsparus didžiosios depresijos sutrikimas, kuris nebuvo atsakyta į ne mažiau kaip dviejų skirtingų gydymo antidepresantais dabartinio vidutinio sunkumo ir sunkios depresijos epizodas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemoraginės karštligės, ebola - vakcinos - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemoraginės karštligės, ebola - vakcinos - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - daugybinė mieloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - daugybinė mieloma - antinavikiniai vaistai - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatos navikai, kastracija-atsparus - antinavikiniai vaistai - treatment of adult patients with prostate cancer.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - daugybinė mieloma - antinavikiniai vaistai - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v.    - rilpivirino hidrochloridas - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - edurant, kartu su kitais antiretrovirusiniais vaistiniais preparatais yra skirtas žmogaus imunodeficito viruso gydymas įveskite 1 (hiv‑1) infekcijos antiretrovirusiniais vaistais pacientams, treatment‑naïve 12 metų ir vyresniems, kurių viremija ≤ 100 000 hiv‑1 rnr kopijų/ml. kaip su kitais antiretrovirusinių vaistų, genotypic atsparumo bandymai turi vadovautis naudojimo edurant.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - kanagliflozinas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5.